Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
Sex Med Rev. 2022 Jul;10(3):376-391. doi: 10.1016/j.sxmr.2022.02.002. Epub 2022 Apr 1.
Due to the prevalence of erectile dysfunction and impotence among men in recent years, several pharmacotherapies have been considered for such problems. Systemic drug therapies in the treatment of erectile dysfunction have significant issues, including drug interactions and contraindications in a wide range of diseases, which makes researchers seek to design drugs and dosage forms with fewer side effects, interactions, and contraindications with maintained efficacy.
5-Phosphodiesterase inhibitors (5-PDEIs or PDE5Is), previously used systemically to treat erectile malfunction, are now appropriate candidates for topical application with considerable potency and fewer complications.
We sought to investigate the recent findings on the current subject in order to provide a comprehensive overview of the issue using an extensive literature search to pinpoint the latest scientific reports on this subject.
In the present review, the function of 5-Phosphodiesterase inhibitors as topical formulations was evaluated with details including formulation type, adsorption, and comparative efficacy in all recent studies as an acceptable alternative therapy to systemic drugs.
Due to the fact that the influential factors in erectile dysfunction interact with many diseases and delinquent treatments, the use of topical therapeutic agents can be promising in mild to moderate cases. The utilization of 5-PDEIs through novel topical and transdermal drug delivery techniques plays a vital role in improving this effectiveness. Hamzehnejadi M, Tavakoli MR, Abiri A, et al. A Review on Phosphodiesterase-5 Inhibitors as a Topical Therapy for Erectile Dysfunction. Sex Med Rev 2022;10:369-384.
近年来，男性勃起功能障碍和阳痿的发病率较高，因此针对这些问题已经考虑了几种药物治疗方法。全身药物治疗勃起功能障碍存在一些重大问题，包括药物相互作用和广泛疾病的禁忌症，这使得研究人员寻求设计具有较少副作用、相互作用和禁忌症的药物和剂型，同时保持疗效。
5-磷酸二酯酶抑制剂（5-PDEIs 或 PDE5Is）以前曾被系统地用于治疗勃起功能障碍，现在是局部应用的合适候选药物，具有相当的效力，并且并发症较少。
我们试图调查目前这一主题的最新发现，以便通过广泛的文献搜索来全面概述这一问题，从而确定关于这一主题的最新科学报告。
在本综述中，评估了 5-磷酸二酯酶抑制剂作为局部制剂的功能，包括制剂类型、吸附以及所有最新研究中的比较疗效，作为全身药物的一种可接受的替代治疗方法。
由于勃起功能障碍的影响因素与许多疾病和不当治疗相互作用，局部治疗剂的使用在轻度至中度病例中可能具有前景。通过新型局部和透皮药物递送技术利用 5-PDEIs 在提高这种有效性方面发挥着重要作用。Hamzehnejadi M、Tavakoli MR、Abiri A 等人。5-磷酸二酯酶抑制剂作为治疗勃起功能障碍的局部治疗方法的综述。性医学评论 2022；10:369-384。
